U.S. District Judge Zahid Quraishi has declined Novo’s bid to halt Eli Lilly’s advertising comparisons between Zepbound and Wegovy. The decision rejects Novo’s request for a preliminary injunction; the underlying false-advertising dispute remains unresolved. For biopharma leaders, the case raises a practical question: how should comparative claims be managed as product development moves beyond the treatments tested in a clinical trial?
New Doses Change the Context of Older Evidence
Novo’s challenge centers on the relevance of the evidence behind Lilly’s promotions. In its court filings, Novo argued that the campaign compared higher doses of Lilly’s treatments with lower doses of its own and failed to adequately reflect a newly approved, higher-dose Wegovy option.
The clinical distinction is important. Zepbound outperformed the original Wegovy in a direct comparative trial. That result supports a conclusion about the treatments studied. It does not establish how Zepbound compares with a subsequent Wegovy formulation that was absent from the trial. Quraishi’s ruling described changes Lilly made to newer advertisements after receiving a cease-and-desist letter. Those versions acknowledge higher-dose Wegovy and explain that it was not included in the comparison. The judge also found that Novo had not demonstrated the commercial harm needed to support its request for an early court order.
A Novo spokesperson emphasized that the decision leaves open whether Lilly’s advertising is misleading. The distinction should guide management’s reading of the case: permission for a campaign to continue at this stage does not settle the merits of its claims.
The issue is pressing because comparative evidence has not kept pace with changes in the commercial setting. Clinicians have more treatment choices as new formulations and doses become available, but earlier trials leave some questions about those choices unanswered.
A More Competitive Market Puts Comparative Claims Under Scrutiny
Wall Street analysts expect the market at the center of this dispute could surpass $100 billion by 2030. Novo initially led its principal competitor, but Lilly has since gained ground. Beyond the injectable comparison, Lilly introduced an oral option soon after Novo launched its Wegovy pill. For commercial teams, a favorable comparative trial offers a clear way to explain a product’s position. Clinicians can use that message only to the extent that the comparison reflects the treatment options available to their patient. When considering a newer dose, a prescriber needs a clear account of what the earlier study showed and the limits of those findings. If those limits are unclear, a valid trial result may be read as a judgment about the whole brand or all its current formulations.
This is the practical management problem behind the litigation. A campaign may retain its original evidence base while the market around it changes. Teams should therefore assess whether the language still gives an appropriate account of current treatment choices, even when the underlying study remains unchanged. The court’s account of Lilly’s revisions illustrates one possible response: preserve the tested comparison while making the untested alternative visible. Whether those disclosures resolve Novo’s broader allegations remains undecided.
Commercial Harm Requires Its Own Evidence
The ruling also draws attention to the operational work needed before a company seeks urgent legal intervention.
At the hearing, Lilly U.S. finance chief Mark Stempel testified that Wegovy prescribing stayed steady during the April-to-July advertising period. Quraishi wrote that Derrick Gastineau, the company’s U.S. vice president for obesity, had made no effort to establish the alleged harm. Those observations supported the judge’s refusal to issue a preliminary injunction. They should not be read as a general finding that comparative advertising cannot affect prescribing. Here, the question was whether Novo had substantiated its request to stop this campaign before the dispute reached a final resolution.
For management, concerns about an advertisement and evidence of its commercial effects are separate workstreams. A scientific objection may identify a mismatch between the trial and the promoted message. A request for immediate relief also needs a supported account of what the campaign is doing to the business.
That calls for earlier coordination between medical, legal and commercial analytics teams. Their review should address:
- Which doses and formulations the cited trial actually tested.
- Whether subsequent product changes alter how audiences may interpret the claim.
- What prescribing evidence supports any allegation of commercial harm.
- Whether the same disclosure standards are applied to the company’s own promotions.
Working through these questions can help teams decide whether a claim needs clarification or a dispute warrants litigation.
Consistent Review Can Support Clearer Treatment Choices
Quraishi also criticized Novo’s promotions for Ozempic. He wrote that advertisements asserting superiority over Lilly’s Trulicity did not disclose an available higher-dose Trulicity version.
That finding introduces a governance issue beyond the immediate contest over Wegovy and Zepbound. A company challenging a competitor’s comparison should expect scrutiny of how it handles similar evidence gaps in its own materials. Consistent review standards may strengthen both promotional oversight and legal decision-making. The care implications are straightforward, although the ruling itself establishes no patient outcome. Comparative advertising can help frame a treatment discussion, but clinicians still need a precise account of the tested populations and regimens. Where a newer option has not been compared directly, the uncertainty should remain visible.
This dispute gives biopharma leaders a reason to review how they maintain promotional claims when approvals change. As new doses and formulations become available, review processes should revisit existing campaigns instead of ending with the original trial. Commercial teams would then have a more defensible message, while clinicians would have a clearer basis for discussing the treatment choices currently available.
